Buy low, sell high is the mantra of the stock market. Turnstone Biologics Corp (NASDAQ: TSBX), a prominent player in the Biotechnology industry, is currently undervalued with a market value of $3.36
compared to its real value of $6.74
. This discrepancy presents a potential opportunity for investors to maximize returns. The analyst overall consensus indicates a 'Buy' with two strong buys, one hold, and an estimated target price of $17, with the highest and lowest estimates being $20
and $13 respectively. This suggests a significant potential for growth. However, it's important to remember that the stock market is unpredictable and it's crucial to conduct thorough research and consider the hype value of 3.5 before doubling your investment. In the current unique economic climate, Turnstone Biologics Corp may present investors with more surprises in the next two to three weeks. We will explore several reasons why the company still has the potential to generate above-average margins and positive cash flow. Currently, Turnstone Biologics Corp is trading at $3.36. The company has a historical hype elasticity of 0.14, while the average price elasticity to hype among its competitors is approximately 1.25.
The firm's value is projected to increase following the next major announcement, with the price expected to rise to $3.5. The current volatility of the media hype's impact on the company's stock price is significantly over 100 percent, making price predictions based on social media less reliable. The price increase following the next news release is projected to be 4.17%, while the daily expected return currently stands at -0.42%.
The volatility of related hype on Turnstone Biologics is about 530.28%, with the expected price after the next announcement by a competitor being $4.61. Given an investment horizon of 90 days, the next forecasted press release is expected to be released very soon.
The successful prediction of Turnstone Biologics stock price
could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices
of traded companies, such as Turnstone Biologics Corp, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value
of Turnstone Biologics based on Turnstone Biologics hews, social hype, general headline patterns, and widely used predictive technical indicators
. We also calculate exposure to Turnstone Biologics's market risk
, different technical
and fundamental indicators
, relevant financial multiples and ratios, and then comparing
them to Turnstone Biologics's related companies.
Use Technical Analysis to project Turnstone expected Price
Turnstone Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Turnstone Biologics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Turnstone Biologics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...
Turnstone Biologics Gross Profit
Turnstone Biologics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Turnstone Biologics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Turnstone Biologics Gross Profit growth over the last 10 years. Please check Turnstone Biologics' gross profit
and other fundamental indicators
for more details.
Breaking down Turnstone Biologics Further
This firm reported the previous year's revenue of 73.3 M
. Net Loss for the year was (30.83 M
) with profit before overhead, payroll, taxes, and interest of 71.13 M
Deferred Revenue Breakdown
Turnstone Biologics Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Deferred Revenue is likely to outpace its year average in 2023. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Where this item is not contained on the company consolidated financial statements and cannot otherwise be imputed the value of 0 is used. At this time, Turnstone Biologics' Deferred Revenue is fairly stable as compared to the past year.
"As the saying goes, 'buy low, sell high,' and it seems that now may be the time to double down on your investment in Turnstone Biologics Corp (USA Stocks: TSBX). Despite a high probability of bankruptcy at 96.76%, the company's potential upside of 24.47 and a target price of $17 suggest a significant return on investment. With a market capitalization of 42.94M
and gross profit of 71.13M
, Turnstone Biologics Corp shows promise. However, investors should be aware of the company's high standard deviation of 15.59, indicating a high level of risk. The company's shares are primarily owned by institutions (34.17%), with insiders owning 8.79%. Despite the risks, the potential rewards may be worth the gamble for those willing to take on a high-risk, high-reward investment strategy."
Turnstone Biologics implied volatility may change after the rise
Turnstone Biologics Corp's stock has recently exhibited significant shifts in its implied volatility, as indicated by the coefficient of variation plunging to -4942.84. This substantial decrease suggests that the stock's volatility is becoming less unpredictable, potentially leading to more consistent trading patterns. However, investors should maintain vigilance as the implied volatility could alter following the recent surge in the stock's value. This could lead to unforeseen price swings, making it essential for investors to closely track Turnstone Biologics' performance in the upcoming weeks. Turnstone Biologics Corp is demonstrating above-average volatility over the chosen time frame. Investors should examine Turnstone Biologics Corp independently to ensure that their intended market timing
strategies align with their expectations about Turnstone Biologics' volatility. Understanding different market volatility
trends often assists investors in timing the market. Proper utilization of volatility indicators allows traders to gauge Turnstone Biologics' stock risk against market volatility during both bullish and bearish trends. The heightened level of volatility that accompanies bear markets can directly affect Turnstone Biologics' stock price
while adding stress to investors as they witness their shares' value decline. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop.
The Bottom Line
While other entities in the biotechnology industry are either recovering or due for a correction, Turnstone may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Turnstone valuation and our trade advice on Turnstone Biologics is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Turnstone Biologics.
for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to firstname.lastname@example.org